Vanda Pharmaceuticals Inc.
VNDA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.01
KIRA · Stoqly’s AI analyst, in plain words
- Vanda Pharmaceuticals Inc. had $216M of revenue in fiscal 2025, up 8.7% on the year before. Over five years, revenue changed −2.7% a year on average.
- Its operating margin was −70.0%, down 49.5 pts: of every 100 in sales, about −70 is left after running the business.
- Vanda Pharmaceuticals Inc. lost $220M in fiscal 2025.
- Free cash flow was −$110M in fiscal 2025, −51.1% of revenue.
Market cap
$242M
P/E
—
Revenue
$216M
Net income
−$220M
Free cash flow
−$110M
Operating margin
−70.0%
Vanda Pharmaceuticals Inc. in 30 seconds · fiscal 2025
Are sales growing?
+8.7%
Yes. Sales grew 8.7% last year.
Does it make a profit?
−102.0%
No. It lost money last year.
Does profit turn into cash?
−51.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Vanda Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 12, 2026
- Legal name
- Vanda Pharmaceuticals Inc.
- CIK
- 0001347178
Vanda Pharmaceuticals Inc. · VNDA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $269M | $254M | $193M | $199M | $216M |
| Revenue growth | 8.3% | −5.3% | −24.3% | 3.2% | 8.7% |
| Operating margin | 15.7% | 2.5% | −7.2% | −20.5% | −70.0% |
| Net income | $33.2M | $6.3M | $2.5M | −$18.9M | −$220M |
| Net margin | 12.3% | 2.5% | 1.3% | −9.5% | −102.0% |
| Diluted EPS | $0.58 | $0.11 | $0.04 | −$0.33 | −$3.74 |
| Cash | |||||
| Cash from operations | $64.2M | $32.0M | $12.8M | −$15.8M | −$109M |
| Capital expenditure | $0.6M | $0.7M | $0.4M | $0.5M | $1.0M |
| Free cash flow | $63.7M | $31.3M | $12.4M | −$16.2M | −$110M |
| FCF margin | 23.7% | 12.3% | 6.4% | −8.2% | −51.1% |
| Share count change | 3.1% | 0.1% | 1.0% | 1.0% | 1.3% |
| Debt and strength | |||||
| Cash and short-term investments | $433M | $135M | $136M | $102M | $84.9M |
| Shareholders' equity | $505M | $527M | $545M | $539M | $327M |
| Current ratio | 6.4x | 5.7x | 4.9x | 4.4x | 2.4x |
| Returns and quality | |||||
| Return on equity | 6.9% | 1.2% | 0.5% | −3.5% | −50.9% |
| Return on tangible equity | 6.8% | 1.2% | 0.6% | −4.5% | −104.9% |
| Piotroski F-score | 5 | 3 | 3 | 2 | 2 |
| Altman Z'' | 10.0 | 8.9 | 8.1 | 6.9 | 0.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.8M
6 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vanda Pharmaceuticals Inc. · VNDA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.01 a share, the company is worth $242M.
Source: SEC EDGAR XBRL filings (CIK 0001347178). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.